Search

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more